CYB003

CYB003 (deupsilocin) is Cybin's deuterated version of psilocin (the active compound in magic mushrooms), running in two Phase 3 trials as an add-on treatment for major depressive disorder (MDD) alongside existing antidepressants [1][2]. The deuterium swap is engineered to shorten the psychedelic experience to roughly 90 minutes while making the pharmacokinetics more predictable, targeting two of psilocybin's biggest commercial liabilities: the cost of clinician-supervised session time and dose-response variability.

Novel first-in-class compound, never approved anywhere. FDA granted Breakthrough Therapy Designation (BTD) to CYB003 in March 2025 for adjunctive treatment of MDD, based on Phase 2 data showing sustained symptom reduction after two doses [3]. Two Phase 3 studies are running in parallel: APPROACH (NCT06564818, n=220, active and no longer recruiting) and EMBRACE (NCT06793397, n=330, recruiting) [1][2]. Both evaluate CYB003 as add-on therapy to an SSRI or SNRI, measured against placebo on the Montgomery-Asberg Depression Rating Scale (MADRS), which runs 0 to 60 with higher scores meaning worse depression. Cybin has publicly targeted a topline readout from APPROACH in the second half of 2026, with a possible New Drug Application (NDA) filing in 2027. A live regulatory question, unresolved on the public record, is whether the FDA will accept a single positive Phase 3 under Breakthrough Designation for MDD or require both APPROACH and EMBRACE to file. The agency has not publicly committed either way for psychedelic MDD, and precedent from Lykos MDMA suggests the bar for a single-trial submission in this space is high. Cybin's pipeline outside CYB003 is thin. CYB004 (deuterated DMT) is in Phase 2, so the company's near-term valuation is tied to the CYB003 readout. Cybin's Q2 fiscal 2026 report (November 2025, for the quarter ended September 30, 2025) disclosed roughly $248M in pro-forma cash after a $175M registered direct offering, projecting 21 to 22 months of runway at the then-current burn [9]. Market cap sits near $243M as of mid-August 2026 [11], so equity is trading roughly at cash, the classic setup for a binary-catalyst pre-revenue biotech.

The 5-HT2A receptor is a serotonin receptor found on the surface of cortical neurons. Activate it hard enough and a psychedelic experience follows. Nichols' 2016 Pharmacological Reviews synthesis is the standard reference for the receptor pharmacology and behavioral pharmacology tying 5-HT2A agonism to the psychedelic state [4]. The antidepressant effect is thought to come from a burst of neuroplasticity: 5-HT2A activation triggers glutamate release and upregulates BDNF, a growth factor that helps neurons form new connections and rebuild cortical circuits atrophied by chronic depression. Whether the subjective psychedelic experience itself is required or merely a side effect is still an open scientific debate. Deuteration is a chemistry trick: swap ordinary hydrogen atoms for deuterium (hydrogen with an extra neutron) at positions where liver enzymes attack the molecule. The heavier carbon-deuterium bond breaks more slowly, so the drug clears less rapidly, the peak plasma concentration is lower, and the curve is smoother. For psilocin, this shortens the intense psychedelic window to roughly 90 minutes versus the 4 to 6 hours seen with psilocybin, cutting supervised clinic time roughly in half [5]. Genetic evidence linking 5-HT2A to MDD is moderate, with Open Targets giving the target a 0.70 association score. Single-dose psilocybin trials at Johns Hopkins and ketamine's rapid-onset antidepressant effect anchored the biological case, and Compass Pathways' COMP360 has now hit two Phase 3 trials in treatment-resistant depression [13], further de-risking the 5-HT2A agonist mechanism, though no such drug is yet FDA-approved.

Two Phase 3 trials, both placebo-controlled adjunctive designs. APPROACH (NCT06564818) enrolls 220 adults with MDD who are on a stable SSRI or SNRI but still symptomatic, randomizing to a 16 mg oral dose of CYB003 or placebo, with a second dose at week 3 and MADRS measured at week 6 [1]. EMBRACE (NCT06793397) is larger at 330 patients with a similar design [2]. Total enrollment across both is 550. Both trials include a music-and-therapy protocol during dosing sessions. The unavoidable problem is functional unblinding. Anyone who receives 16 mg of an active psychedelic knows within 20 minutes, and anyone getting placebo also knows. This inflates the drug-arm response through expectancy effects and can be devastating at FDA review. The Lykos MDMA advisory committee in June 2024 voted 9 to 2 that available data did not demonstrate the drug was effective, and 10 to 1 that benefits did not outweigh risks, with functional unblinding central to both votes [6]. Cybin's mitigation is enrolling patients naive to psychedelics, using a remote MADRS rater blinded to session events, and running a validated blinding integrity measure. Whether the FDA accepts this remains untested for MDD. Enrollment: APPROACH stopped enrolling on schedule; EMBRACE is still recruiting and pace has not been publicly disclosed in detail. A miss on EMBRACE enrollment would push the second readout past 2026.

Our model estimates a 10% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 51%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is held back by heavier-than-usual blinding, the sponsor's thin or weak approval record, weak or limited earlier-phase results, and a randomized design. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk is the largest single item. Functional unblinding makes any measured drug-placebo delta suspect, and the Lykos MDMA advisory committee voted 9 to 2 that data did not demonstrate efficacy, and 10 to 1 that benefits did not outweigh risks, largely on this issue [6]. If placebo response inflates from an unblinded trial, a real 5-point MADRS advantage can shrink toward statistical noise. Safety risk clusters in two areas. Serotonin 5-HT2B agonism, which psilocin has to some degree, is linked to valvular heart disease. This is the mechanism that pulled fenfluramine (fen-phen) off the market after Connolly and colleagues reported valvular abnormalities, with Roth's 2007 NEJM commentary summarizing the receptor pharmacology tying it to 5-HT2B activation [14]. Cybin argues the intermittent dosing schedule (two lifetime doses in the trial) avoids the chronic exposure that drove those cases, but a Phase 3 safety database will draw echocardiogram scrutiny. Suicidality signals in psychiatric trials draw immediate FDA attention, and the Lykos submission had this problem. Execution risk sits with EMBRACE enrollment pace and cash. Cybin's Q2 fiscal 2026 report (November 2025) showed roughly $248M pro-forma cash after a $175M registered direct offering, projecting 21 to 22 months of runway at the then-current $28.5M quarterly burn [9]. That extends into mid-2027, past the APPROACH readout, but repeated equity raises are already diluting existing holders and any delayed readout would likely force another. Commercial risk persists even on approval. Reimbursement for supervised psychedelic sessions is unresolved. Compass Pathways has been fighting this battle publicly, and CMS (Centers for Medicare & Medicaid Services) has not yet set clear coding for psychedelic-assisted therapy [10]. Payers may cover the drug but balk at the clinic-day cost, capping addressable revenue below what a straightforward pill would command.

Worth watching, and one of the few genuinely binary catalysts in psychiatric drug development for 2026. The specific data point that would turn CYB003 from noise to signal is the APPROACH topline in the second half of 2026. Three things to look for: a MADRS delta of 4 points or more (context: the scale runs 0 to 60, a typical MDD patient enrolls around 30 to 35, and modern SSRIs beat placebo by roughly 2 to 3 points, so a 4-point advantage is a genuine step up worth paying for), a p-value (probability the observed drug-placebo delta arose by chance) that survives functional-unblinding scrutiny (Cybin should publish the blinding integrity analysis alongside efficacy), and cardiac safety data with a clean echocardiogram cohort. The competitive picture has shifted materially. Compass Pathways' COMP360 has already hit both Phase 3 trials in TRD with an NDA planned for Q4 2026 [13], which de-risks the 5-HT2A agonist mechanism but also removes the 'category monopoly' scenario that earlier commentary sometimes assumed. MindMed's MM120 (lysergide oral disintegrating tablet) is in three Phase 3 trials: the Voyage GAD (generalized anxiety disorder) topline is expected in the first half of 2026, Panorama GAD in the second half of 2026, and the Emerge MDD study is enrolling with topline expected in the mid-to-late 2026 window [12]. A MindMed MDD hit could land near the CYB003 window and split the adjunctive-MDD opportunity on session duration, dosing profile, and formulation. Beyond the direct psychedelic entrants, Atai Life Sciences' portfolio and the USONA Institute non-profit psilocybin program add further crowding. Deuteration is the composition-of-matter moat that theoretically extends CYB003 exclusivity well past natural psilocybin, but the exact patent expiry date is not disclosed in Cybin's public materials and should be verified from the patent filings before sizing terminal value. As of mid-August 2026 the market cap is near $243M [11] against $248M pro-forma cash reported in November 2025 [9]. Equity is trading approximately at cash, which is unusual for a company with a positive Phase 2 and BTD approaching Phase 3 readout, and reflects both dilution risk and market skepticism after Lykos. This is a company that will roughly triple or lose 70% of its equity value on the APPROACH readout. Check back in Q4 2026 for APPROACH data; earlier if Cybin discloses EMBRACE enrollment completion or any safety pause.